**Appendix Table1. Clinical properties of the ovarian cancer patients used in the analysis.**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Dataset | No. of tumor samples involved | No. of  normal  samples  involved | Death event | Median overall survival  (Mon) | Serous/  Endometrioid/  Clear cell/  Mucinous/  Others | Grade  (1/2/3) | Stage  (1/2/3/4) | Debulking  (Optimal/  Suboptimal) | Primary therapy outcome  (Complete Remission/  Partial Remission/  Progressive Disease/  Stable Disease) | Age | History of neoadjuvant  treatment  (Yes/No) | Initial pathologic  Diagnosis method  (Tumor resection/  Cytology/Other) |
| TCGA | 376 | 0 | 235 | 17.267 | 376/0/0/0/0 | 2/49/314 | 4/24/294/49 | 256/72 | 205/44/29/24 | 34~87 | 1/374 | 310/41/25 |
| GTEX | 0 | 88  (ovary  samples) | NA | NA | NA | NA | NA | NA | NA | 20~60 | NA | NA |
| GSE  26712 | 28 | 185 | 129 | 38.28 | NA | High① | Late② | 90/95 | NA | NA | NA | NA |
| GSE  63885 | 101 | 0 | 66 | 36.83 | 72/12/9/0/7 | 0/10/51 | 0/2/64/11 | 15/60 | NA | NA | NA | NA |

①No specific grade shown.

②No specific stage shown

NA, data not available; /out of, total number of patients with available clinical data